This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lainchbury, J. G. Articles by Richards, A. M. Search for Related Content PubMed Articles by Lainchbury, J. G. Articles by Richards, A. M. Related Collections Related Articles

CLINICAL RESEARCH: HEART FAILURE

N-Terminal Pro–B-Type Natriuretic Peptide-Guided Treatment for Chronic Heart Failure

Results From the BATTLESCARRED (NT-proBNP–Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) Trial

Department of Medicine, Christchurch Cardioendocrine Research Group, University of Otago, Christchurch, New Zealand

Manuscript received November 26, 2008; revised manuscript received February 19, 2009, accepted February 24, 2009.

^_* Reprint requests and correspondence: Dr. A. Mark Richards, The Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, P.O. Box 4345, Christchurch 8140, New Zealand (Email: mark.richards{at}cdhb.govt.nz).

Objectives: The purpose of this study was to compare the effects of N-terminal pro–B-type natriuretic peptide (NT-proBNP)-guided therapy with those of intensive clinical management and with usual care (UC) on clinical outcomes in chronic symptomatic heart failure.

Background: Initial trial results suggest titration of therapy guided by serial plasma B-type natriuretic peptide levels improves outcomes in patients with chronic heart failure, but the concept has not received widespread acceptance. Accordingly, we conducted a longer-term study comparing the effects of NT-proBNP–guided therapy with those of intensive clinical management and with UC of patients with heart failure.

Methods: Three hundred sixty-four patients admitted to a single hospital with heart failure were randomly allocated 1:1:1 (stratified by age) to therapy guided by NT-proBNP levels or by intensive clinical management, or according to UC. Treatment strategies were applied for 2 years with follow-up to 3 years.

Results: One-year mortality was less in both the hormone- (9.1%) and clinically-guided (9.1%) groups compared with UC (18.9%; p = 0.03). Three-year mortality was selectively reduced in patients 75 years of age receiving hormone-guided treatment (15.5%) compared with their peers receiving either clinically managed treatment (30.9%; p = 0.048) or UC (31.3%; p = 0.021).

Conclusions: Intensive management of chronic heart failure improves 1-year mortality compared with UC. Compared with clinically guided treatment and UC, hormone-guided treatment selectively improves longer-term mortality in patients 75 years of age. (NT-proBNP–Assisted Treatment To Lessen Serial Cardiac Readmissions and Death [BATTLESCARRED]; Australian New Zealand Clinical Trials Registry 12605000735651)

Key Words: NT-proBNP • chronic heart failure • survival

Abbreviations and Acronyms   ACEI = angiotensin-converting enzyme inhibitor   ARB = angiotensin receptor blocker   BB = beta-adrenergic blocker   BNP = B-type natriuretic peptide   CG = clinically guided   CHF = chronic heart failure   LVEF = left ventricular ejection fraction   NT-proBNP = N-terminal pro–B-type natriuretic peptide   NYHA = New York Heart Association   UC = usual care

Related Articles

Warning on Diuretic Use

Morten Grundtvig, Arne Westheim, Torstein Hole, Berit Flønæs, Lars Gullestad on behalf of the Norwegian Heart Failure Registry
J. Am. Coll. Cardiol. 2010 55: 2609-2610. [Full Text] [PDF]

This article has been cited by other articles:

				P. K. Bonfils, M. Damgaard, M. Taskiran, J. P. Goetze, P. Norsk, and N. Gadsboll Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure Eur J Heart Fail, July 8, 2010; (2010) hfq100v1. [Abstract] [Full Text] [PDF]

				M. Grundtvig, A. Westheim, T. Hole, B. Flonaes, L. Gullestad, and on behalf of the Norwegian Heart Failure Registry Warning on Diuretic Use. J. Am. Coll. Cardiol., June 8, 2010; 55(23): 2609 - 2610. [Full Text] [PDF]

				A. M. Richards and for the BATTLESCARRED Trial Authors Reply. J. Am. Coll. Cardiol., June 8, 2010; 55(23): 2610 - 2610. [Full Text] [PDF]

				T. G. Yandle and R. W. Troughton Improving risk stratification in heart failure: a role for new biomarkers? Eur J Heart Fail, April 1, 2010; 12(4): 315 - 318. [Full Text] [PDF]

				N-Terminal pro-B-type Natriuretic Peptide Is "Battle-Scarred" in Another Heart Failure Trial Journal Watch Cardiology, February 10, 2010; 2010(210): 1 - 1. [Full Text]

				M. G. Daly, C. M. Frampton, and R. W. Troughton Improving Risk Stratification for Heart Failure: A Role for Serial Testing of B-Type Natriuretic Peptides? J. Am. Coll. Cardiol., February 2, 2010; 55(5): 451 - 453. [Full Text] [PDF]

				A. Maisel Natriuretic Peptide-Guided Therapy for Heart Failure: Ready for "Battle" or Too "Scarred" by the Challenges of Trial Design? J. Am. Coll. Cardiol., January 5, 2010; 55(1): 61 - 64. [Full Text] [PDF]